RDEA: Valeant has an option to license this compound [RDEA-806] post phase 2B and pre phase 3.
For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.